Altered Tumor Oxygenation by Metformin, a Potential Step in Overcoming Radiotherapy Resistance in LACC
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
Poor tumor oxygenation (hypoxia) is an established negative prognostic and predictive factor
in locally advanced cervical cancer (LACC). Hypoxia-modifying measures implemented in the
clinic are lacking.
Metformin is a well-known, well-tolerated and low-cost drug used for decades in the treatment
of type 2- diabetes. Recent studies suggest an improved tumor oxygenation by metformin
potentially improving radiotherapy response and patient outcome.
This study is a randomized, phase II, open label study in patients with LACC where patients
are randomized to standard cisplatin-based chemoradiotherapy +/- Metformin.
Metformin will be started one week prior to the start of chemoradiotherapy, and will be
continued throughout the entire radiation treatment.
Tumor oxygenation will be evaluated by gene signatures and MRI- parameters.